Where BioPharma Is Relocating

For most of the past half-century, the geography of US biopharma was a settled question. New Jersey housed the headquarters of the industry’s largest companies — Merck in Kenilworth, Johnson & Johnson in New Brunswick, Novartis US in East Hanover, Sanofi US in Bridgewater. The Boston/Cambridge corridor served as the innovation engine, with Kendall Square concentrating more biotech R&D per square mile than any other location on Earth. San Francisco and the Bay Area maintained a substantial cluster anchored by Genentech in South San Francisco. This three-hub structure was stable enough that careers could be planned around it: a pharma executive who wanted commercial leadership moved to New Jersey; one who wanted R&D moved to Boston; one who wanted to work at a platform biotech moved to the Bay Area.

That structure has materially changed. Between 2020 and 2025, the traditional NJ pharma corridor lost approximately 15% of its headquarters-level executive positions as companies consolidated, relocated R&D functions to Boston, and shifted commercial operations to newer hubs. Simultaneously, Boston/Cambridge continued to grow, the Research Triangle in North Carolina emerged as a genuine fourth hub, San Diego built critical mass in specific therapeutic areas, and cities like Nashville and Denver began attracting biopharma operations for the first time at scale. This piece maps the current geography of US biopharma and its implications for senior life sciences professionals making career decisions.

NJ pharma corridor decline

The New Jersey pharma corridor — the stretch of central New Jersey from Princeton to Morristown that housed the US headquarters of more than a dozen major pharmaceutical companies — has experienced a structural contraction that is more fundamental than a cyclical downturn. Three forces have converged to reduce NJ’s share of pharma executive employment.

R&D consolidation to Boston. Multiple large pharma companies that historically maintained NJ-based R&D operations have shifted those functions to the Boston/Cambridge area to access the biotech talent pool and the academic research ecosystem. Sanofi’s move of its global R&D headquarters from Bridgewater, NJ to Cambridge, MA was the most visible example, but the pattern extends across the industry. Companies that once ran parallel R&D sites in NJ and Boston have consolidated to Boston, reducing NJ executive headcount by 20–30% at the VP+ level.

Commercial operations decentralization. The traditional model of running US commercial operations from a NJ headquarters with field teams deployed nationally has been replaced by a more distributed model. Several major pharma companies now run commercial operations from multiple hubs, with regional commercial VPs based in their territories rather than commuting to NJ. This decentralization has reduced the concentration of senior commercial roles in the NJ corridor.

Cost and talent competition. NJ’s high cost of living, combined with state income taxes that are among the highest in the country, has made the corridor less competitive for attracting senior talent compared to emerging hubs in the Southeast and Texas. The professionals who remain in NJ tend to be deeply embedded in the local pharma network; the ones who leave tend to be mid-career executives who see better opportunities in Boston, the Research Triangle, or remote-friendly roles at companies headquartered elsewhere.

The NJ corridor is not disappearing — Merck, J&J, and several other major companies maintain significant NJ operations. But its share of total US pharma VP+ employment has declined from roughly 28% in 2018 to approximately 20% in 2025, and the trend shows no sign of reversing.

Boston/Cambridge growth

Boston/Cambridge has been the primary beneficiary of the geographic reshuffling, consolidating its position as the dominant US biopharma hub. The Kendall Square and Seaport biotech clusters now house the US R&D operations of most major global pharma companies alongside the largest concentration of clinical-stage biotech companies in the world. The region’s advantages are structural and self-reinforcing: proximity to Harvard, MIT, and the Broad Institute provides a continuous supply of scientific talent; the density of biotech companies creates a deep executive talent pool that enables rapid hiring; and the concentration of venture capital (roughly 40% of all US biotech VC is deployed in the Boston area) sustains new company formation.

VP-level compensation in Boston/Cambridge biotech reflects the market’s dominance. Median VP R&D total compensation at clinical-stage companies is $520,000 to $620,000 — the highest in the country and 15–20% above equivalent roles in NJ, San Diego, or the Research Triangle. The premium reflects both the cost of living (Greater Boston housing is among the most expensive in the US) and the intensity of competition for experienced executives in a market where multiple companies are recruiting for the same specialized profiles simultaneously.

The limitation of Boston’s dominance is that it is increasingly expensive for both companies and executives. Lab rents in Kendall Square have reached $100+ per square foot NNN, pushing smaller biotechs to Watertown, Waltham, and the suburbs along the Route 128 corridor. Executive housing costs have risen even faster, with the median home price in the communities favored by pharma executives (Wellesley, Brookline, Newton, Lexington) exceeding $1.5 million. These cost pressures are one of the factors driving the growth of alternative hubs.

Research Triangle emergence

The Research Triangle (Raleigh-Durham-Chapel Hill) has emerged as the fastest-growing biopharma hub in the United States, driven by a combination of academic research infrastructure (Duke, UNC, NC State), favorable business climate, and a cost of living that is roughly 40% below Boston. The Triangle’s biopharma presence has evolved from a handful of large pharma manufacturing and commercial operations (the legacy of GSK’s Research Triangle Park campus and Merck’s Durham operations) to a diversified ecosystem that includes clinical-stage biotechs, CROs, and a growing digital health segment.

The most significant recent development has been the relocation and expansion of pharma companies that are building Research Triangle operations as alternatives to NJ or Boston. Multiple companies have announced RTP-area expansions in 2024–2025, creating senior leadership demand across R&D, clinical operations, manufacturing, and commercial functions. VP-level compensation in the Research Triangle ranges from $380,000 to $500,000 — roughly 20–25% below Boston equivalents on a gross basis, but with North Carolina’s 4.75% flat state income tax and dramatically lower housing costs, the net-income comparison is much more favorable.

For life sciences executives considering the Research Triangle, the value proposition is the combination of growing institutional infrastructure, a talent pool that is deepening rapidly, and a quality of life that is genuinely superior to the Northeast corridor for families. The limitation is ecosystem density: the Triangle does not yet have the concentration of early-stage biotechs and venture capital that Boston offers, meaning the executive network is thinner and the set of potential next moves is smaller.

San Diego biotech cluster

San Diego’s biotech cluster has maintained a distinctive identity within the US biopharma landscape, with particular strength in genomics, immunology, and antibody engineering. The cluster is anchored by companies like Illumina (genomics), Neurocrine Biosciences (neuroscience), and the Scripps Research Institute, with a growing concentration of ADC (antibody-drug conjugate) and cell therapy companies that have established San Diego operations in the past three years.

The San Diego market is smaller than Boston or the Bay Area but offers specific advantages for certain executive profiles. VP-level compensation ranges from $440,000 to $580,000 — below Bay Area levels but above the Research Triangle and Texas, reflecting California state income tax and a cost of living that, while lower than San Francisco, remains above the national average. The city’s strongest executive talent pool is in research leadership and early-stage drug discovery; its relative weakness is in late-stage clinical development and commercial operations, where the candidate universe is thinner than in Boston or NJ.

San Diego’s growth trajectory in biopharma is steady rather than explosive. The city is unlikely to challenge Boston’s dominance in the near term, but for executives who want to work in a research-intensive biotech environment without the cost and congestion of the Bay Area or the Northeast, San Diego offers a compelling combination of scientific quality, climate, and career opportunity.

Emerging hubs: Nashville and Denver

Two cities that deserve attention as emerging biopharma hubs are Nashville and Denver, each building life sciences presence from different starting points. Nashville’s healthcare industry concentration — the city is headquarters to HCA Healthcare, Vanderbilt University Medical Center, and a cluster of healthcare services companies — has begun to attract pharma commercial and medical affairs operations. VP-level roles at Nashville-based healthcare and life sciences companies paid $360,000 to $460,000 in our 2025 data, with the premium reflecting the relatively small local talent pool and the relocation incentives needed to attract candidates from traditional pharma hubs.

Denver’s life sciences presence is earlier-stage and more concentrated in medical devices, health technology, and clinical research services. The city’s quality of life, growing tech ecosystem, and position as a regional hub for the Mountain West create a foundation for life sciences growth, though the current executive talent pool is thin relative to established hubs. VP-level compensation in Denver life sciences ranges from $370,000 to $480,000, with Colorado’s 4.4% flat state income tax providing a modest advantage over California and Massachusetts but less dramatic than Texas or Florida’s zero-tax environment.

Neither Nashville nor Denver is likely to become a primary biopharma hub in the near term. Their significance is as destinations for specific executive profiles: commercial and medical affairs leaders who want to live in the Southeast or Mountain West while maintaining pharma careers, and operations executives who are building local teams for companies expanding beyond the traditional coastal hubs.

Talent implications

The geographic diversification of US biopharma has specific implications for senior executives making career decisions. The most important: geographic flexibility is now a career asset in a way it wasn’t a decade ago. An executive who is willing to consider roles in the Research Triangle, San Diego, or Houston alongside the traditional Boston and NJ markets has access to a significantly larger set of opportunities — and often faces less competition for those roles because the candidate pool willing to relocate is smaller.

The compensation geography has also shifted. The traditional model, where NJ and Boston paid the highest pharma executive salaries because of their dominant market positions, has been complicated by the emergence of markets that pay lower gross compensation but offer materially higher net disposable income. A VP of Clinical Development earning $440,000 in the Research Triangle may have more disposable income than the same VP earning $560,000 in Boston, once state income tax and housing costs are properly accounted for.

For life sciences executives at the mid-career stage (Director to VP transition), the most strategically valuable geographic move may be to an emerging hub where the executive can build a leadership position in a less competitive talent market. The professionals who established themselves in the Research Triangle or San Diego biotech clusters five years ago are now among the most sought-after candidates in those markets, with career trajectory advantages that would have been much harder to achieve in the more crowded Boston ecosystem. For current compensation benchmarks across all US life sciences markets, see our 2026 Compensation Report.